Zeocin™

Zeocin™


Order number: M3446.0250

Shipping: shipped at RT, store at +2°C to +8°C
CAS-Nr: 11006-33-0

Ready to ship today,
Delivery time 1-3 workdays

€147.97 *

Weight:

Please select the favoured pack size.

Zeocin(TM) belongs to the structurally related group of bleomycin/phleomycin type antibiotics.... more
Product information "Zeocin™"

Zeocin(TM) belongs to the structurally related group of bleomycin/phleomycin type antibiotics. It is used as a selective agent in transformation experiments with mammalian cells, plant cells and yeast. The cytotoxic effect results from the ability to cause fragmentation of DNA. Zeocin(TM) binds to DNA through its amino-terminal peptide, and the activated complex generates free radicals that are responsible for scission of the DNA chain. Zeocin(TM) is used as a selective agent for the incorporation of the Sh ble gene which encodes a 13,665 dalton protein. The encoded protein prevents damage of DNA by binding to Zeocin(TM), thus inhibiting the binding to DNA. Zeocin(TM) is a trademark of Cayla.

More products around "Zeocin™"
Specifications: Appearance: blue powder Solubility: easily soluble in water C 55 H 85 O 21 N... more
 

Technical Data:

Specifications:
Appearance: blue powder
Solubility: easily soluble in water
C55H85O21N20S2Cu x HCl
MW = 1525 g/mol

application:

Zeocin™ causes cell death by intercalating into DNA and cleaving it. The action of Zeocin™ is effective on most aerobic cells. Zeocin™ is used at a concentration of 50-300µg/ml for selection in mammalian cells and 25µg/ml for bacterial selection.

Source

Streptomyces verticullus

Sicherheits Hinweise / Safety

H-Sätze: H302
GHS-Symbole: GHS07
R-Sätze: Xn
Gefahrstoffkürzel: R22

Klassifizierungen / Classification

CAS-Nr: 11006-33-0
eclass-Nr: 32-16-04-05
Dokumente - Protokolle - Downloads more


Dokumente - Protokolle - Downloads

Here you will find information and further literature on Zeocin™. For further documents (certificates with additional lot numbers, safety data sheets in other languages, further product information) please contact Genaxxon biosience at: info@genaxxon.com or phone: +49 731 3608 123.

 
 
 
Dokumente - Protokolle - Downloads more

Dokumente - Protokolle - Downloads

Zeocin™ Selection in E. coli

Host: Must not contain the Tn5 transposon (i.e. TOP10, DH5, DH10).
Medium: Use Low Salt LB Medium (10g Tryptone, 5g NaCl, and 5g Yeast Extract) at pH7.5 to prevent inactivation of Zeocin™.
Selection: Use 25-50μg/mL of Zeocin™ for selection in E. coli.

Zeocin™ Selection in Yeast

Yeast: Saccharomyces cerevisiae, Pichia pastoris
Medium: YPD with 1M sorbitol (electroporated cells); YPD or minimal plates (chemically transformed cells). Test the medium adjusted to pH values ranging from 6.5-8.0 and select the pH that allows you to use lowest Zeocin™ concentration.
Transformation Method: Use electroporation, lithium cation protocols, or EasyComp™ Kits. Do not use spheroplasting for yeast transformation with Zeocin™ containing plasmids as it results in complete cell death.
Selection: Use 50-300μg/mL of Zeocin™, depending on the yeast strain, and media pH and ionic strength. Perform a kill curve to determine the lowest Zeocin concentration required to kill the untransformed host strain.

Note: Allow the cells to recover for 1 hour in YPD medium after transformation. To obtain efficient Zeocin™ selection, plate at low cell densities (use 10, 25, 50, 100, and 200 μL of transformation reaction).

 
 
 
Literatur .... more

Referenzen..

 

Hier finden Sie Artikel und Literaturzitate, in denen die Autoren auf die hohe Qualität dieses Genaxxonprodukts vertrauen.
Listed below are articles and references, in which the authors trust in the high quality of this Genaxxon product.

Quelle/Source: NCBI PubMed >

Activity of neutral and alkaline ceramidases on fluorogenic N-acylated coumarin-containing aminodiols

Mireia Casasampere, Luz Camacho, Francesca Cingolani, Josefina Casas, Meritxell Egido-Gabás, José Luís Abad, Carmen Bedia, Ruijuan Xu, Kai Wang, Daniel Canals, Yusuf A. Hannun, Cungui Mao, Gemma Fabrias

J Lipid Res. 2015 Oct; 56(10): 2019–2028. doi: 10.1194/jlr.D061564

Correction in: 

J Lipid Res. 2016 Aug; 57(8): 1598.

PMCID: PMC4583077